Skip to NavigationSkip to content


Former Insys sales exec sentenced to a year in prison for offering lap dances to encourage fentanyl spray prescriptions

A sales executive at the disgraced and bankrupted firm Insys who was accused of offering lap dances in order to persuade physicians to prescribe the company’s addictive opioid painkiller products has been sentenced to a year and a day in prison, it has emerged.

Sunrise Lee, former Regional Director for the firm and a former stripper, was handed one of the most severe sentences so far in the ongoing legal case.

Insys Therapeutics files for bankruptcy

Opioid drugmaker Insys Therapeutics has filed for Chapter 11 bankruptcy protection after agreeing to pay $225 million to settle charges brought against them by the Department of Justice (DoJ).

On 5 June, the Arizona-based firm agreed to pay $225 million to the DoJ, just a month after four former executives and Insys founder John Kapoor were found guilty of engaging in a racketeering conspiracy surrounding its fentanyl spray Subsys.

Top Ten most popular articles on this week!

Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a disreputable doctor a lap dance in an effort to persuade him to prescribe the potent opioid fentanyl to his patients. Meanwhile Vertex terminated COO Ian Smith over ‘personal behaviour’ while an Israeli biotech made the dubious claim that it had created a complete cure for cancer.

Stripper-turned-Insys sales rep gave lap dance to persuade doctor to prescribe fentanyl

A pharmaceutical executive working for Insys therapeutics has been accused of giving a doctor a lap dance in an effort to persuade him to prescribe a fentanyl spray to his patients.

Sunrise Lee, the woman accused of giving the lap dance, was hired by Insys as a regional sales manager, despite having no experience in the pharmaceutical industry.

Formerly an exotic dancer, Lee while acting as a sales rep gave a doctor a lap dance at a Chicago club while pushing the potent opioid painkiller, Subsys.

Insys Therapeutics reaches $150m agreement to settle opioid marketing case

The Arizona-based pharma company Insys Therapeutics has reached an agreement to pay $150 million to the US Department of Justice in order to settle criminal and civil investigations into inappropriate sales and commercial practices by former company employees.

The terms of the agreement call for the opioid drug maker to pay $150 million over five years.  The settlement agreement also covered the potential for an additional $75 million contingency based payments.

FDA rejects Insys Therapeutics sublingual opioid spray

US regulators FDA building

The FDA has rejected Insys Therapeutics buprenorphine sublingual spray due to concerns about the safety of the Arizona-based company’s opioid painkiller.

The US regulator’s decision has come after the FDA advisory committee voted 18-1 against approval of the treatment. The American company sought approval for the sublingual spray, which uses the active ingredient buprenorphine, for the treatment of moderate to severe acute pain earlier this year. However the FDA has rejected the application due to potential safety concerns.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches